Secondly, it is important to acknowledge that administration of mineralocorticoid receptor agonists (MRAs) and sodium–glucose cotransporter 2 (SGLT2) inhibitors lowers the risk of atrial arrhythmia recurrence following AF ablation [31,32]. The gene discussed is NR3C2; the disease is atrial fibrillation.